204 related articles for article (PubMed ID: 28939005)
21. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
Lovre D; Htun W; Carrion C; Fonseca VA
Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
[TBL] [Abstract][Full Text] [Related]
22. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Kuritzky L; Umpierrez G; Ekoé JM; Mancillas-Adame L; Landó LF
Postgrad Med; 2014 Oct; 126(6):60-72. PubMed ID: 25414935
[TBL] [Abstract][Full Text] [Related]
24. Antidiabetic Drugs as Antihypertensives: New Data on the Horizon.
Mamakou V; Eleftheriadou I; Katsiki N; Makrilakis K; Tsioufis K; Tentolouris N
Curr Vasc Pharmacol; 2017; 16(1):70-78. PubMed ID: 29032756
[TBL] [Abstract][Full Text] [Related]
25. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
[TBL] [Abstract][Full Text] [Related]
26. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic choices, and the nurse practitioner's role, in type 2 diabetes when metformin alone is no longer enough.
Tierney K
J Am Acad Nurse Pract; 2012 Apr; 24 Suppl 1():234-48. PubMed ID: 22564100
[TBL] [Abstract][Full Text] [Related]
28. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
29. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
Scheen AJ
Diabetes Metab; 2007 Feb; 33(1):3-12. PubMed ID: 17258489
[TBL] [Abstract][Full Text] [Related]
30. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
31. New insights into antidiabetic drugs: Possible applications in cancer treatment.
Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Zarghami N
Chem Biol Drug Des; 2017 Dec; 90(6):1056-1066. PubMed ID: 28456998
[TBL] [Abstract][Full Text] [Related]
32. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
33. Understanding the cardiovascular risk with non-insulin antidiabetic drugs.
Athyros VG; Imprialos K; Stavropoulos K; Sahinidis A; Doumas M
Expert Opin Drug Saf; 2019 Mar; 18(3):241-251. PubMed ID: 30810055
[TBL] [Abstract][Full Text] [Related]
34. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
35. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
[TBL] [Abstract][Full Text] [Related]
36. Managing type 2 diabetes: going beyond glycemic control.
Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
[TBL] [Abstract][Full Text] [Related]
37. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
Horsdal HT; Mehnert F; Rungby J; Johnsen SP
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
[TBL] [Abstract][Full Text] [Related]
38. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Cardoso S; Moreira PI
Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
[TBL] [Abstract][Full Text] [Related]
39. Genetically proxied antidiabetic drugs targets and stroke risk.
Zhu Y; Li M; Wang H; Yang F; Pang X; Du R; Zhang J; Huang X
J Transl Med; 2023 Sep; 21(1):681. PubMed ID: 37777789
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.
Gore MO; McGuire DK
Curr Cardiol Rep; 2009 Jul; 11(4):258-63. PubMed ID: 19563725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
